Skip to content

GH研究制药

US · GHRS #2969 按市值排名 上市于 2021
18.15 -0.66 -3.51%
实时 - 追踪5344个代码 - 心跳于14秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 机构持股总比例下降了4.1个百分点。

机构持股

机构持股比例
71.20% -4.07pp
机构数量
72
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund30.04%
Hedge Fund25.93%
Individual/Insider24.46%
VC/PE Fund13.36%
Public Company1.38%
Private Company0.49%
Other4.34%

主要股东 截至 2026-04-01

Florian Schonharting 21.60% · 14.82M 股
Lynx1 Capital Management LP 19.32% · 13.26M 股
BVF Partners L.P. 12.60% · 8.65M 股
FMR 8.71% · 5.98M 股
RTW Investments, LP 8.64% · 5.93M 股
RA Capital Management, L.P. 7.13% · 4.90M 股
Deep Track Capital, LP 4.86% · 3.33M 股
Avoro Capital Advisors LLC 2.62% · 1.80M 股
Theis Terwey 2.60% · 1.78M 股
Foresite Capital Management, LLC 1.37% · 940.49K 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪13份申报 · 4次买入 · 0次卖出

姓名职务持股比例
Florian Schonharting Co-Founder & Non-Executive Chairman of the Board 21.60%
Magnus Halle Co-Founder & MD of Ireland 0.17%
Michael Forer Independent Vice Chairperson 0.07%
Duncan Moore Independent Non-Executive Director 0.02%
Dermot Hanley Independent Non-Executive Director 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-07 Florian Schonharting Co-Founder & Non-Executive Chairman of the Board Other Derivative Acquisition +2,303 $0.03
2026-08-10 Michael Forer Independent Vice Chairperson Other Derivative Acquisition +102,202 $0.03
2026-08-10 Dermot Hanley Independent Non-Executive Director Other Derivative Acquisition +2,202 $0.03
2026-08-10 Duncan Moore Independent Non-Executive Director Other Derivative Acquisition +2,202 $0.03
2026-03-31 Florian Schonharting Co-Founder & Non-Executive Chairman of the Board Initial Statement of Beneficial 0 --
2026-03-17 Michael Forer Independent Vice Chairperson Initial Statement of Beneficial 0 --
2026-03-17 Dermot Hanley Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Duncan Moore Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Magnus Halle Co-Founder & MD of Ireland Initial Statement of Beneficial 0 --

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

GH研究制药 讨论区 0 条评论

发表评论